Medtronic InterStim® Therapy for Urinary Control
Medtronic InterStim Therapy for urinary control has been shown to successfully treat certain bladder control problems in patients for whom more conservative treatments were unsuccessful. InterStim Therapy addresses the nerve component of bladder control problems by sending mild electrical pulses to the sacral nerve which influences the bladder and surrounding muscles that manage urinary function.
InterStim Therapy for is indicated for the treatment of non-obstructive urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments. It is not indicated for mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture.
Patients must undergo a trial assessment period, known as Peripheral Nerve Evaluation (PNE). Through a simple, in-office procedure, the physician places a temporary lead that is connected to a small external test stimulator. The trial assessment allows the patient to experience the effects of the therapy for approximately 3-7 days to help the patient and physician determine if long-term therapy will be beneficial.
Peripheral Nerve Evaluation Procedure
- Minimally-invasive, office-based procedure done under local anesthetic
- Can be performed with or without fluoroscopy
- Lead placement procedure typically takes 30-60 minutes
- Allows patient to experience the effects of the stimulation to determine whether the therapy is beneficial
- Helps physician and patient make an informed choice regarding the long-term therapeutic value
- Safe and fully reversible
Note: Complications can occur with the trial assessment, including movement of the wire, technical problems with the device, and some temporary pain.
If the PNE test is inconclusive or unsuccessful, a chronic lead test is recommended. This test utilizes a tined (chronic) lead, to reduce migration. Placement of the tined lead is performed through an outpatient procedure and is connected to the same external stimulator. With conclusive test results, this lead can remain in place and the implantable neurostimulator (INS) and lead extension would then be implanted.
Placement of the Permanent InterStim Tined Lead and Implantable Neurostimulator (INS)
Patient-reported results will allow the physician and the patient to make an informed choice regarding the long-term therapeutic success of the therapy. Permanent implantation of the InterStim tined lead and INS is performed after a successful PNE or chronic lead test.
Physician training is required prior to implantation of InterStim components and the product technical manual must be reviewed for detailed, step-by-step instructions of the implant procedure. A summary of the InterStim II device implant procedure is presented below:
|
|
|
Using bony topography or fluoroscopy as a guide, |
|
Stimulation is applied to confirm appropriate |
|
|
|
|
|
|
|
The tined lead is placed into the introducer and |
|
Once appropriate placement of the lead is |
|
|
|
|
|
The lead is connected to the INS header. |
|
The INS is placed in the subcutaneous pocket |
|
Pocket is closed. |
For additional information on InterStim Therapy and educational opportunities, visit http://professional.medtronic.com/sns
InterStim® Therapy for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
Contraindications: Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.
Warning: This therapy is not intended for patients with mechanical |
---|
Precautions/Adverse Events:
Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins such as multiple sclerosis. The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/ screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic’s website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.
USA Rx Only. Rev 0409
- ‹ previous
- 8 of 18
- next ›